Published in Vaccine Weekly, April 5th, 2000
"We tested the safety and immunogenicity of a synthetic Plasmodium falciparum multi-antigen, CS peptide (MAP) vaccine adsorbed to alum and mixed with the adjuvant QS-21," explained R. Edelman and colleagues from Aquila Biopharmaceuticals and from several universities in the United States.
Edelman et al. presented data from their study at the 48th Annual Meeting of the American Society of Tropical Medicine and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.